Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecast
ARWR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 15 analysts
- Price target
- $107.71 average of analyst targets
- Upside to target
- +92.7% from the latest close
- Next earnings
- November 24, 2026 EPS estimate $-1.59
- 52-week range
- $37.35 – $89.59
ARWR analyst ratings
15 analystsNumber of analysts at each rating.
ARWR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ARWR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$1.37 | −$1.75 | −$1.00 | $0.22 | −721.0% | 7 |
| Current fiscal year (FY2026) | −$3.51 | −$5.14 | −$2.45 | −$0.01 | −35,034.2% | 15 |
| Next fiscal year (FY2027) | −$4.98 | −$6.58 | −$2.66 | −$3.51 | −41.7% | 15 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ARWR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $45.8M | $30.0M | $66.8M | −82.7% | 6 |
| Current fiscal year (FY2026) | $464.1M | $417.5M | $590.7M | −44.0% | 16 |
| Next fiscal year (FY2027) | $328.2M | $114.2M | $800.0M | −29.3% | 16 |
ARWR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ARWR revenue: reported and forecast
ARWR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$1.35 | −$1.41 | −$1.34 | −$1.37 | −$1.37 | +1.0% | 0 up · 1 down |
| Current fiscal year (FY2026) | −$3.08 | −$3.51 | −$3.54 | −$3.54 | −$3.51 | +13.9% | 0 up · 6 down |
| Next fiscal year (FY2027) | −$4.57 | −$4.87 | −$4.80 | −$4.93 | −$4.98 | +9.0% | 0 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ARWR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ARWR beat in 4 of 12.
What analysts expect from ARWR
15 analysts cover Arrowhead Pharmaceuticals; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $107.71, 92.7% above the latest close of $55.90. Analysts expect earnings of −$3.51 per share for FY2026, −35,034.2% from a year earlier. For FY2027 the average estimate is −$4.98 per share on revenue of $328.2 million. Arrowhead Pharmaceuticals beat the EPS estimate in 4 of the last 12 quarters.
Related: ARWR income statement, ARWR key metrics, ARWR chart. See the ARWR stock overview for the latest quote and news.
ARWR forecast FAQ
What is Arrowhead Pharmaceuticals's price target?
The average analyst price target for Arrowhead Pharmaceuticals is $107.71, 92.7% above the latest close of $55.90.
Is Arrowhead Pharmaceuticals a buy, hold or sell?
Of 15 analysts covering Arrowhead Pharmaceuticals, 10 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Arrowhead Pharmaceuticals's EPS forecast?
Analysts forecast −$3.51 per share for FY2026 (range −$5.14 to −$2.45); for FY2027 the estimate is −$4.98.
What is Arrowhead Pharmaceuticals's revenue forecast?
The average revenue estimate for FY2026 is $464.1 million, growth of −44.0%; for FY2027 it is $328.2 million.
When does Arrowhead Pharmaceuticals report earnings?
Arrowhead Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 24, 2026 after the market closes; the EPS estimate is $-1.59.
Does Arrowhead Pharmaceuticals usually beat earnings estimates?
Arrowhead Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 12 quarters.